Cy5.5 NHS ester for BBB nanoparticle imaging

Cy5.5 NHS ester (non-sulfonated) is a useful near-infrared fluorescent dye for biomolecule labeling when the experimental question requires covalent tracking rather than transient dye association. Its NHS ester reacts with primary amines on lysine residues, amine-terminated peptides, or modified oligonucleotides to form stable amide bonds. APExBIO supplies the product as a solid under SKU A8103, with the Cy5.5 NHS ester (non-sulfonated) product information reporting excitation and emission maxima of approximately 684 and 710 nm, respectively.

That spectral position makes the reagent relevant to near-infrared fluorescence imaging, including biodistribution studies of engineered nanoparticles. The reference study on MOF-based nanoparticles for non-invasive sononeuromodulation in epilepsy provides a particularly useful application context: a brain-targeted, ultrasound-responsive platform must be tracked in vivo without confusing particle localization with ultrasound activity or therapeutic outcome. The study does not report use of Cy5.5 NHS ester, so the workflow below is a practical assay adaptation rather than a claim that the dye was part of the published platform.

Setup and principle overview

Why the NHS ester chemistry matters

The NHS ester is most reactive toward unprotonated primary amines in mildly alkaline aqueous conditions. Amine-free buffers are therefore preferred during conjugation; Tris, glycine, and other primary-amine-containing components can consume activated dye before it reaches the intended target. Because the non-sulfonated dye has low aqueous solubility, prepare a concentrated stock in an organic solvent such as anhydrous DMSO or DMF, then add it gradually to the buffered biomolecule.

The product information lists a molecular weight of 716.31, an extinction coefficient of 209,000 M⁻¹cm⁻¹, and a quantum yield of 0.2. These values support absorbance-based estimation of labeling, but the calculated degree of labeling should be treated as an approximation when the conjugate contains light-scattering nanoparticles, multiple chromophores, or strongly absorbing payloads. Protect both solid and solution from prolonged light exposure, and use freshly prepared dye solutions promptly because they are not intended for long-term storage.

Choose the labeling target before opening the vial

For a soluble protein, identify the desired balance between signal and retained activity. A high dye-to-protein ratio can increase brightness while also changing charge, hydrophobicity, receptor binding, or clearance. For an amine-modified oligonucleotide, confirm that the terminal amine is accessible and that the sequence does not contain unanticipated reactive modifications. For MOF-based or polymeric nanoparticles, first determine whether the surface exposes primary amines directly or through a targeting ligand, coating, or linker.

Include at least four controls: unlabeled material, free-dye control, labeled material without the biological trigger, and a labeled material with the targeting ligand omitted or blocked. These controls are especially important for in vivo fluorescence imaging because residual free dye can distribute differently from the conjugated construct and produce a misleading tissue signal.

Step-by-step conjugation workflow

Protocol Parameters

• Dye stock: Dissolve Cy5.5 NHS ester at 1–5 mM in anhydrous DMSO or DMF, prepare 10–50 µL immediately before use, and keep the tube protected from light.
• Biomolecule solution: Use protein, peptide, or amine-modified oligonucleotide at 0.5–2 mg/mL in 100–500 µL of phosphate or bicarbonate buffer at pH 7.5–8.5.
• Starting stoichiometry: Add 3–10 molar equivalents of dye per accessible amine and incubate for 20–60 min at 20–25°C with gentle mixing.
• Organic-solvent limit: Add the dye stock slowly to keep final DMSO or DMF at 1–10% v/v, then mix for 5 min before the main incubation.
• Quenching: Add glycine or another validated primary-amine quencher to 10–20 mM and incubate for 10–15 min at 20–25°C in the dark.
• Purification: Remove free dye by size-exclusion chromatography using 1–5 mL of equilibrated resin, or by dialysis with a 10–30 kDa molecular-weight cutoff for 2–4 h at 4°C with two buffer exchanges.

Practical execution

First, equilibrate the biomolecule in an amine-free buffer and record its concentration. If the starting material is in Tris or glycine, exchange it before adding the dye. Second, calculate the dye volume from the number of accessible amines rather than simply using total protein mass. For a lysine-rich protein, begin with the lower end of the 3–10-equivalent range and increase only if the signal is inadequate.

Third, add the organic dye stock dropwise while gently mixing. Avoid vortexing delicate proteins or nanoparticle suspensions because bubbles and high shear can create aggregation. Maintain the reaction in the dark at room temperature. After quenching, separate the conjugate from free Cy5.5 NHS ester using a method appropriate for molecular size. Size-exclusion chromatography is often preferable for a protein or nanoparticle conjugate because it is rapid and avoids prolonged exposure to dialysis membranes.

Finally, characterize both chemistry and function. Measure absorbance near the dye maximum and at a protein-specific wavelength when appropriate, then estimate dye loading after correcting for spectral overlap. Confirm the conjugate by SDS-PAGE fluorescence, analytical SEC, mass spectrometry, or gel-based oligonucleotide analysis. For nanoparticles, pair fluorescence with hydrodynamic size, polydispersity, zeta potential, and colloidal stability measurements. A bright sample is not automatically a successful conjugate if its size or targeting behavior has changed.

Key Innovation from the Reference Study

The reference study develops MOF-based piezoelectric nanoparticles, described as PUANPs, that are activated by ultrasound to generate localized electrical signals for non-invasive neuromodulation. Its central innovation combines several functions in one platform: brain-targeting ligands for blood-brain barrier transport, ultrasound-triggered effects, and platinum nanoclusters intended to improve piezoelectric performance while attenuating neuroinflammation and oxidative stress in epileptic foci. These findings are summarized in the reference study on MOF-based nanoparticles enabling blood-brain barrier crossing.

Cy5.5 NHS ester can translate that design into a trackable assay by labeling an exposed amine on the targeting ligand, a surface coating, or a deliberately introduced amine-bearing handle. The most informative experiment is not simply a whole-animal fluorescence image. Instead, compare labeled targeted PUANPs with labeled untargeted particles, free dye, and ultrasound-free controls; then examine blood, peripheral organs, and brain regions at matched time points. This lets investigators ask whether a fluorescent signal reflects intact nanoparticle accumulation, nonspecific vascular retention, or free-dye leakage.

Why this cross-domain matters, maturity, and limitations

The bridge from a fluorescent conjugation reagent to an epilepsy nanomedicine workflow is valuable because imaging can reveal delivery efficiency before functional neuromodulation studies become expensive or difficult to interpret. However, it remains an assay-development step. The reference study establishes the platform concept and its targeting, ultrasound, and microenvironment-regulation strategy; it does not establish that Cy5.5 labeling preserves PUANP piezoelectric behavior, receptor-mediated transport, or therapeutic efficacy.

Accordingly, label a small pilot batch first and compare its physicochemical properties with unlabeled PUANPs. Test ultrasound responsiveness, ligand-dependent uptake, and cell viability after labeling. Keep dye loading low enough to preserve the surface chemistry under investigation, and use a separate unlabeled batch for any endpoint in which the fluorophore could alter charge, aggregation, or protein adsorption. Fluorescence should be interpreted as a distribution readout, not as direct evidence of neuronal inhibition, BBB crossing, or reduced inflammation.

Advanced applications and comparative advantages

Tracking brain-targeted nanoparticles

The 684/710 nm excitation-emission pair is suited to near-infrared fluorescence imaging workflows in which tissue autofluorescence and visible-light background complicate detection. For a BBB study, label the carrier, targeting ligand, or cargo-bearing construct in separate pilot experiments rather than assuming that all fluorescent signals report the same molecular species. If the dye is attached only to the ligand, signal loss may indicate ligand cleavage or degradation rather than nanoparticle clearance.

For quantitative comparisons, normalize fluorescence to injected dose, tissue mass, acquisition exposure, and an internal calibration standard. Ex vivo organ imaging can complement whole-animal images and help identify whether apparent brain accumulation is actually signal from blood retained in the vasculature. These safeguards are also relevant to optical imaging of tumors, where heterogeneous perfusion and nonspecific retention can produce the same interpretive problem.

Protein and oligonucleotide conjugates

As a fluorescent dye for protein conjugation, the reagent can support receptor-binding assays, uptake studies, microscopy, and flow cytometry. Protein labeling is most useful when the degree of labeling is measured and the native activity is tested in parallel. Amine-modified oligonucleotides offer a second route for constructing fluorescent probes, but purification must remove hydrolyzed dye and unconjugated oligonucleotide because both can distort hybridization or uptake measurements.

The previously published guide Cy5.5 NHS Ester for NIR Biomolecule Imaging complements this workflow by discussing protein, peptide, and amine-modified nucleic-acid labeling. The present article extends that foundation to nanoparticle tracking and adds controls designed for BBB and ultrasound studies. For a broader discussion of spectral behavior and in vivo imaging considerations, Cy5.5 NHS Ester (Non-Sulfonated): Near-Infrared Fluorescence provides a related resource rather than a substitute for product-specific validation.

Troubleshooting and optimization tips

• Visible precipitate after dye addition: The non-sulfonated reagent is poorly soluble in water. Prepare a 1–5 mM DMSO or DMF stock, add it slowly, and keep the final organic solvent near or below 10% v/v. If precipitation persists, lower the dye equivalent and increase biomolecule concentration within its stability range.
• Low labeling or weak fluorescence: Check that the reaction pH is 7.5–8.5 and that the buffer does not contain competing primary amines. Use a fresh stock rather than a solution stored for days, and confirm that the instrument is configured near 684 nm excitation and 710 nm emission.
• High background after purification: Run a free-dye control through the same purification method and collect multiple fractions. A second SEC pass or a 2–4 h dialysis with two buffer changes may be needed for a high-sensitivity assay.
• Aggregation of a nanoparticle conjugate: Reduce the dye-to-amine ratio from 10 to 3 equivalents, shorten incubation from 60 to 20 min, and compare size and polydispersity before and after labeling. Do not use brightness alone to select the best condition.
• Loss of receptor binding or uptake: Compare low and high labeling batches, such as approximately 0.5–2 dyes per protein or targeting ligand when compatible with the construct. Measure binding independently because near-infrared signal cannot prove that the recognition domain remains active.
• Unexpected brain or tumor signal: Include dye-only, untargeted-particle, and perfusion-controlled samples. Free Cy5.5, vascular retention, and tissue autofluorescence can all mimic specific delivery in in vivo fluorescence imaging.

Future outlook

The most defensible next step is a paired imaging-and-function study in which Cy5.5-labeled and unlabeled PUANPs are tested side by side. Fluorescence can map carrier distribution and support time-course sampling, while separate assays determine whether labeling preserves ultrasound responsiveness, brain targeting, and the biological effects described in the reference platform. This design keeps localization evidence separate from mechanistic and therapeutic conclusions.

More broadly, the combination of covalent amine labeling and near-infrared readout can make complex biomolecule and nanoparticle workflows easier to audit. Progress will depend on optimizing dye density, proving conjugate stability, and validating that the fluorophore does not change the surface properties being studied. With those controls in place, Cy5.5 NHS ester (non-sulfonated) offers a practical route from chemical labeling to interpretable near-infrared tracking in molecular, cellular, and translational imaging experiments.